The expression levels of BCL-2 in liver and serum have been found to be down-regulated in NAFLD/NASH patients, suggesting that BCL-2 play an important role in hepatocyte apoptosis in NAFLD/NASH. This evidence concerns the gene BCL2 and metabolic dysfunction-associated steatohepatitis.